Dr. Rob Hilgers
Assistant Professor
Pharmaceutical Sciences
Campbell University
United States of America
Biography
Dr. Rob Hilgers obtained his Ph.D degree in Pharmacology at the University of Maastricht, the Netherlands in 2004. He has substantial postdoctoral research experience in cardiovascular-related diseases conducted at prestigious universities in Europe and the United States. His particular interests involves studying the molecular mechanisms of endothelial dysfunction in resistance arteries in experimental animal models of hypertension, aging and obesity-induced diabetes.His main expertise is the application of myograph systems to assess ex vivo vascular reactivity and structure in correlation with pharmacological interventions. He is particularly interested in the role of endothelial calcium-activated potassium channels in relation to cellular redox status.
Research Interest
Pharmacology
Publications
-
Hilgers RH, Das KC. Role of In Vivo Vascular Redox in Resistance ArteriesNovelty and Significance. Hypertension. 2015 Jan 1;65(1):130-9.
-
Subramani J, Kundumani-Sridharan V, Hilgers RH, Owens C, Das KC. Thioredoxin uses a GSH-independent route to deglutathionylate endothelial nitric-oxide synthase and protect against myocardial infarction. Journal of Biological Chemistry. 2016 Nov 4;291(45):23374-89.
-
Hilgers RH, Kundumani-Sridharan V, Subramani J, Chen LC, Cuello LG, Rusch NJ, Das KC. Thioredoxin reverses age-related hypertension by chronically improving vascular redox and restoring eNOS function. Science translational medicine. 2017 Feb 8;9(376):eaaf6094.
